Literature DB >> 10634172

Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes.

A Ali1, S D Mundle, D Ragasa, S Reza, V Shetty, B Y Mativi, J D Cartlidge, M Azharuddin, H Qawi, S Dar, A Raza.   

Abstract

Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by the concomitant presence of peripheral cytopenias and normocellular to hypercellular BM. This paradox has been proposed to be due to the presence of excessive proliferation matched by excessive intramedullary apoptosis of hematopoietic cells. When cultured in vitro MDS BM mononuclear cells (BMMC) undergo apoptosis within 4 h. We measured caspase-1-like and caspase-3-like activity in 22 MDS and 4 normal BM immediately following cell separation or after 4 h culture. When cultured in vitro, MDS BMMC demonstrated an increased apoptotic index within 4 h as measured by in situ end-labeling of fragmented DNA that was matched by a concurrent increase in caspase-3-like specific activity, and the two were significantly correlated. During the 4 h culture, a sequential activation of caspase-1-like and caspase-3-like activities was detected. Caspase-1-like specific activity was detected early and transiently at approximately 15 min, followed by a gradual increase in caspase-3-like-specific activity peaking at 2 h. When the broad-spectrum caspase inhibitor, Z-VAD.FMK, was included in the MDS BM aspirate 4 h culture, apoptosis was attenuated. We conclude that sequential activation of caspase-1-like and caspase-3-like activities may form the central biochemical pathway of apoptosis in BMMC from some MDS patients, and prevention of this process by caspase inhibitors may be of significant therapeutic value for these patients, in whom supportive care continues to be the mainstay of therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10634172     DOI: 10.1089/152581699320108

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  6 in total

Review 1.  The end is just the beginning: megakaryocyte apoptosis and platelet release.

Authors:  J Li; D J Kuter
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 3.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.

Authors:  Jane E Parker; Ghulam J Mufti
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

5.  Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines.

Authors:  P Greenberg
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 6.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.